Topic: Metabolic and Endocrine
Conditions
Interventions
58 patients with biopsy proven steatosis due to non-alcoholic fatty liver disease (NAFLD) will be randomised to 3.5 g n-3 polyunsaturated fatty acid (PUFA) or oleic enriched sunflower oil capsules for
Sponsors
University of Nottingham (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age greater than 18 years, either sex 2. Liver biopsy showing NAFLD
Exclusion criteria
Exclusion criteria: 1. Excessive alcohol intake - greater than 21 units per week in men and greater than 14 in women 2. A further liver disease diagnosis 3. Poorly controlled diabetes - HbA1c greater than 8.0% 4. Pregnancy 5. Cirrhosis 6. Significant inflammation on liver biopsy - classified as a Brunt moderate or severe 7. Life expectancy of less than 2 years 8. Contraindications to MR scanning - pacemaker or metallic foreign body 9. Changes in the dose or initiation of lipid altering medication within the preceeding three months, such as statins, fibrates or systemic steroids 10. Use of n-3 PUFA supplements within the prior 4 months, an adequate washout period
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Measured pre- and post-intervention: 1. Liver biochemistry 2. Lipid profile 3. Insulin resistance 4. Blood pressure 5. Abdominal visceral fat 6. Inflammatory cytokine profile | — |
Primary
| Measure | Time frame |
|---|---|
| Hepatic steatosis as determined by magnetic resonance imaging (MRI) spectroscopy pre- and post-intervention Liver fat stores (MR spectroscopy), measured pre- and post-intervention | — |
Countries
United Kingdom
Outcome results
None listed